Log In Get Started
Press Releases May 18, 2026 04:15 PM

Certara to Participate in Upcoming Investor Conferences

Certara announces participation in multiple upcoming investor conferences with live webcasts.

By Derek Hwang CERT

Certara, Inc., a leader in model-informed drug development, will participate in several investor conferences including RBC CM Global Healthcare, William Blair’s Growth Stock, and Jefferies Global Healthcare Conferences. The company will provide live webcasts of select events accessible through its investor relations website.

Certara to Participate in Upcoming Investor Conferences
CERT

Key Points

  • Certara engages actively with investors through scheduled participation in prominent healthcare and growth stock conferences.
  • Live webcasts available for select conference presentations, improving transparency and investor communication.
  • The company positions itself as a global leader in biosimulation software and services for drug development, serving a broad client base across biopharmaceutical firms, academia, and regulatory bodies.

RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

  • RBC CM Global Healthcare Conference
    Date and Time: Tuesday, May 19 at 9:30 a.m. ET
  • William Blair’s 46th Annual Growth Stock Conference
    Date: Tuesday, June 2
  • Jefferies Global Healthcare Conference
    Date: Wednesday, June 3 at 1:20 p.m. ET

Live webcasts for the RBC and Jefferies conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.

Investor Relations Contact:
David Deuchler
Gilmartin Group
[email protected]

Media Contact:
Alyssa Horowitz
[email protected]


Risks

  • Market and investor response to conference presentations may be uncertain and could impact stock volatility.
  • The company's performance is highly dependent on the pharmaceutical and healthcare sectors, which can be affected by regulatory changes and market competition.
  • Technology advancements or disruptions in biosimulation and drug development could impact Certara's competitive position.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026